Watch the video to learn about:

  • The current treatment options for 2nd line and 3rd line gastric and gastroesophageal cancers
  • Treatment selection strategies
  • The latest research and clinical trials in 2nd line and 3rd line treatments

The video is divided into chapters for your convenience.

Build upon your learning further and download the accompanying slide set for your reference.


Clinical Takeaways

  • Overall survival in patients with advanced gastric and GE cancers has improved with more effective systemic therapy

  • Current therapies in the second line and beyond setting may not be reflective of the changing landscape of first-line therapy in advanced disease, but trials are ongoing

  • Factors to consider when evaluating a patient for the second line and beyond therapy include prior lines of therapy and residual toxicities, performance status and competing comorbidities

  • PTX+RAM is the standard of care for second-line treatment, but there are multiple candidates for third-line treatment, which is not clearly defined

  • For HER2-positive gastric cancer, T-DXd was shown to be effective after trastsuzumab failure. Currently, the development of second-line therapy after trastsuzumab failure is the focus of attention

Dr Cheng Ean Chee is an Assistant Professor of Medicine at Yong Loo Lin School of Medicine, National University of Singapore, Singapore. She completed medical school at University College London, United Kingdom and Internal Medicine Residency and Hematology-Oncology Fellowship at Mayo Clinic, Rochester, Minnesota, USA. Dr Chee is a clinician-investigator and medical oncologist in gastrointestinal and hepatobiliary cancers at the National University Cancer Institute, Singapore. She is also involved in phase I drug development and is the principal investigator of several phase I and gastrointestinal cancer trials at her institution. As the Program Director for the NUHS Medical Oncology Senior Residency (Fellowship) Program, she is actively involved in the education of the Medical Oncology trainees and she also chairs the Colorectal Cancer Committee of the Singapore Cancer Society. She is an active member of ASCO and the Asian Colorectal Cancer Oncology Group.

Asst. Prof. Cheng Ean Chee has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca (Advisory Board)

Dr Hisato Kawakami is an assistant professor in charge of clinical trials/research for gastrointestinal malignancies at the Department of Medical Oncology, Kindai University Faculty of Medicine in Osaka, Japan, where he has been employed since 2010. His professional specialty is medical oncology and gastroenterology, and his main research interests include molecular-targeted therapy and immunotherapy for gastrointestinal cancer.

Dr Kawakami graduated from Kumamoto University, earned his medical degree from Japanese Ministry of Health, Labor and Welfare, and his doctorate of philosophy from Kindai University. He currently utilises his expertise in scientific rationale-based translation of novel drugs, including molecular targeted therapy and immuno-oncology therapy, to develop and improve treatment strategies.

Dr Hisato Kawakami has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Consulting fees from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd., and Taiho Pharmaceutical Co. Ltd; honoraria from Bristol-Myers Squibb Co. Ltd., Bayer Yakuhin Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck Biopharma Co., Ltd., Takeda Pharmaceutical Co. Ltd., Yakult Pharmaceutical Industry, Teijin Pharma Ltd., and Taiho Pharmaceutical Co. Ltd.; lecture fees from Glaxo Smith Kline K.K., and Otsuka Pharmaceutical Co., Ltd.; and research funding from Chugai Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd, Kobayashi Pharmaceutical. Co., Ltd., and Eisai Co. Ltd. 

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre.  

Meet the experts

Other programmes of interest

other Other
Oncology 
Biomarker testing in NSCLC: patient and caregiver awareness and understanding

Findings from a global survey presented in a poster at ESMO 2024

Experts
Prof. Christian Rolfo, Prof. Fernando López-Ríos, Dr. Rodrigo Paredes, Amy Moore, Anne-Marie Baird, Shani Shilo
Endorsed by
LUNGevity
Lung Cancer Europe IASLC
The Israeli Lung Cancer Foundation ISLB
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2024

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Podcast
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Sep 2024

Educational programme supported by an Independent Educational Grant from Ipsen
conference-update Conference update
Oncology 
ESMO 2024: New data on GI, lung, HCC, breast and GU cancers

Renowned medical experts share their insights into new data presented at ESMO 2024

  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Sep 2024

animated-video Animated Video

Episode

1

of 1

episode
Oncology 
Precision oncology in prostate cancer: tips for optimal genomic testing

From sample collection through to diagnostic modalities 

Experts
Dr Alexander Wyatt
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2024

Educational programme supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.
video Video
Oncology Hemato-oncology 
Early relapsed/refractory multiple myeloma (RRMM): best practices in management

A 3-part video series on managing early RRMM from leading medical experts

Experts
Dr Elena Zamagni, Dr Fredrik Schjesvold, Dr Joseph Mikhael
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Sep 2024

Educational programme supported by an Independent Educational Grant from Menarini Stemline Oncology.
other Other

Episode

2

of 2

episode
Oncology 
Optimising samples for biomarker testing in lung, prostate and gastric cancer

Recommendations for best practice

Experts
Dr Alexander Wyatt, Prof. Frédéric Bibeau
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Aug 2024

Educational programme supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.